Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 12pembrolizumab 7Carboplatin 7Cisplatin 6Docetaxel 5sargramostim 4Taxes 4Cyclophosphamide 4Amifostine 4Trastuzumab 3Polymerase Chain Reaction 3Nivolumab 3Irinotecan 3Gemcitabine 3Etoposide 3talazoparib 2aldesleukin 2Vorinostat 2Vinorelbine 2SS1(dsFv)PE38 2Pemetrexed 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Erlotinib Hydrochloride 2tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × quisinostat × Thoracic × Clear all
NCT02728492 2016-05-03

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

NewVac LLC

Phase 1 Completed
51 enrolled
GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡